Research location

Zhanjiang

China

Published trials38

Site observations41

Linked trials published38

Page1 / 1

Research activity in Zhanjiang

China

CureCurrent currently publishes aggregate city-level research activity for this location: 38 trials and 41 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Zhanjiang

38 linked trials · page 1 of 1

Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 AgonistNCT07718724 · 2026-09-05 · 1 site observation

Phase 3b Study in Patients With Severe Asthma Treated With TezepelumabNCT07363642 · 2026-01-28 · 1 site observation

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22 · 1 site observation

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypeNCT07190209 · 2025-09-16 · 1 site observation

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 InflammationNCT06959095 · 2025-06-20 · 1 site observation

A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese PopulationNCT06419413 · 2024-01-08 · 1 site observation

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerNCT06119581 · 2023-12-21 · 1 site observation

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)NCT06103864 · 2023-11-23 · 1 site observation

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe AsthmaNCT06023589 · 2023-08-24 · 1 site observation

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With AsthmaNCT06609239 · 2024-09-30 · 1 site observation

ENROLLING_BY_INVITATION

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsNCT06635447 · 2024-09-26 · 1 site observation

ACTIVE_NOT_RECRUITING

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe AsthmaNCT06102005 · 2023-10-16 · 1 site observation

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).NCT05742802 · 2023-03-06 · 1 site observation

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04 · 1 site observation

ACTIVE_NOT_RECRUITING

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyNCT05450692 · 2022-09-15 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseNCT05400369 · 2022-08-10 · 1 site observation

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT05221840 · 2022-02-07 · 1 site observation

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.NCT05158387 · 2022-02-07 · 1 site observation

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled AsthmaNCT04937387 · 2021-07-29 · 2 site observations

A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)NCT04636801 · 2021-07-14 · 1 site observation

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 MutationsNCT04695925 · 2021-03-29 · 1 site observation

ACTIVE_NOT_RECRUITING

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic PhenotypeNCT04719832 · 2021-03-17 · 1 site observation

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)NCT04609904 · 2021-03-01 · 1 site observation

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)NCT04701983 · 2020-12-16 · 1 site observation

Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in ChinaNCT04853225 · 2020-04-22 · 1 site observation

Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .NCT04234620 · 2020-02-15 · 1 site observation

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer PatientsNCT04154956 · 2020-02-06 · 1 site observation

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent ExacerbationsNCT04053634 · 2019-08-26 · 1 site observation

A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus SecretionsNCT03843541 · 2019-06-25 · 1 site observation

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 InflammationNCT03930732 · 2019-04-15 · 1 site observation

Efficacy and Safety Study of Dupilumab in Patients With Persistent AsthmaNCT03782532 · 2019-01-25 · 1 site observation

Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)NCT03186209 · 2017-09-07 · 1 site observation

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).NCT03164616 · 2017-06-01 · 1 site observation

ACTIVE_NOT_RECRUITING

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)NCT03043872 · 2017-03-27 · 1 site observation

ACTIVE_NOT_RECRUITING

Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD PatientsNCT03022097 · 2017-02-02 · 1 site observation

Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young WomenNCT02914158 · 2016-03-30 · 3 site observations

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)NCT02465567 · 2015-06-30 · 1 site observation

The Efficacy and Safety Study in Patients With Type 2 Diabetes MellitusNCT01608724 · 2012-11-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.